99 related articles for article (PubMed ID: 8926574)
1. In vivo time-dependent inhibition of human steroid 5 alpha-reductase by finasteride.
Tian G
J Pharm Sci; 1996 Jan; 85(1):106-11. PubMed ID: 8926574
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat.
Stuart JD; Lee FW; Simpson Noel D; Kadwell SH; Overton LK; Hoffman CR; Kost TA; Tippin TK; Yeager RL; Batchelor KW; Bramson HN
Biochem Pharmacol; 2001 Oct; 62(7):933-42. PubMed ID: 11543729
[TBL] [Abstract][Full Text] [Related]
3. 17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1.
Tian G; Stuart JD; Moss ML; Domanico PL; Bramson HN; Patel IR; Kadwell SH; Overton LK; Kost TA; Mook RA
Biochemistry; 1994 Mar; 33(8):2291-6. PubMed ID: 8117686
[TBL] [Abstract][Full Text] [Related]
4. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies.
Tian G; Mook RA; Moss ML; Frye SV
Biochemistry; 1995 Oct; 34(41):13453-9. PubMed ID: 7577933
[TBL] [Abstract][Full Text] [Related]
6. Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics.
Suzuki R; Satoh H; Ohtani H; Hori S; Sawada Y
Drug Metab Pharmacokinet; 2010; 25(2):208-13. PubMed ID: 20460827
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological and clinical profile of finasteride (PROPECIA)].
Fukuzumi H; Ikeda T; Narita H; Takubo T; Matsuda T; Taniguchi T
Nihon Yakurigaku Zasshi; 2006 Jun; 127(6):495-502. PubMed ID: 16880702
[No Abstract] [Full Text] [Related]
8. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
Makridakis N; Reichardt JK
J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
[TBL] [Abstract][Full Text] [Related]
9. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic-like properties of 5-alpha-reductase inhibitors.
Bortolato M; Frau R; Orrù M; Bourov Y; Marrosu F; Mereu G; Devoto P; Gessa GL
Neuropsychopharmacology; 2008 Dec; 33(13):3146-56. PubMed ID: 18354385
[TBL] [Abstract][Full Text] [Related]
11. Validation of a population pharmacokinetic/pharmacodynamic model for 5 alpha-reductase inhibitors.
Olsson Gisleskog P; Hermann D; Hammarlund-Udenaes M; Karlsson MO
Eur J Pharm Sci; 1999 Aug; 8(4):291-9. PubMed ID: 10425379
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human steroid 5alpha reductases type I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanism.
Moss ML; Kuzmic P; Stuart JD; Tian G; Peranteau AG; Frye SV; Kadwell SH; Kost TA; Overton LK; Patel IR
Biochemistry; 1996 Mar; 35(11):3457-64. PubMed ID: 8639496
[TBL] [Abstract][Full Text] [Related]
13. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
[TBL] [Abstract][Full Text] [Related]
14. 5 alpha-reductase inhibitors, chemical and clinical models.
Guarna A; Occhiato EG; Danza G; Conti A; Serio M
Steroids; 1998; 63(5-6):355-61. PubMed ID: 9618802
[TBL] [Abstract][Full Text] [Related]
15. Linear relationships between the ligand binding energy and the activation energy of time-dependent inhibition of steroid 5alpha-reductase by delta 1-4-azasteroids.
Tian G; Haffner CD
J Biol Chem; 2001 Jun; 276(24):21359-64. PubMed ID: 11279132
[TBL] [Abstract][Full Text] [Related]
16. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR.
Bramson HN; Hermann D; Batchelor KW; Lee FW; James MK; Frye SV
J Pharmacol Exp Ther; 1997 Sep; 282(3):1496-502. PubMed ID: 9316864
[TBL] [Abstract][Full Text] [Related]
17. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency.
Imperato-McGinley J; Shackleton C; Orlic S; Stoner E
J Clin Endocrinol Metab; 1990 Mar; 70(3):777-82. PubMed ID: 1689740
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor.
Ko HC; Jusko WJ
Pharmacotherapy; 1995; 15(4):509-11. PubMed ID: 7479205
[TBL] [Abstract][Full Text] [Related]
19. Mechanism based representation of the active site of 5 alpha-reductase (5AR).
Ahmed S; Denison S
Bioorg Med Chem Lett; 1998 Sep; 8(18):2615-70. PubMed ID: 9873591
[TBL] [Abstract][Full Text] [Related]
20. 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.
Cabeza M; Quiroz A; Bratoeff E; García G; Ramírez E; Flores E
Proc West Pharmacol Soc; 2002; 45():164-5. PubMed ID: 12434569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
